However, no drugs targeting the SST system are approved or under investigation in clinical trials for the treatment of neurodegenerative and psychiatric disorders, mainly because current SST analogs cannot penetrate the blood–brain barrier (Lamberts et al., 1996). The gene discussed is SST; the disease is psychiatric disorder.